Taken together, these data support the proposition that the changes that occur in 1,25D metabolism during CKD may be reversible by therapeutics targeting defective iron handling, potentially through lowering FGF23, but not to levels that could cause further increases in serum phosphate. This evidence concerns the gene FGF23 and chronic kidney disease.